{"id":6841,"date":"2025-04-04T11:55:26","date_gmt":"2025-04-04T09:55:26","guid":{"rendered":"https:\/\/darkgreen-crane-601020.hostingersite.com\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/"},"modified":"2025-07-10T13:34:31","modified_gmt":"2025-07-10T11:34:31","slug":"financing-and-other-arrangements","status":"publish","type":"page","link":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/","title":{"rendered":"Financing and other arrangements"},"content":{"rendered":"<ul>\n<li><u>A brief description of the financing of the study<\/u>, including information about the financial source(s) and what this funding cover. It is assumed that the intervention period is financially secured.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li><u>Description of any compensation for the study participants<\/u>. This also includes a description of how participants&#8217; eventual expenses are to be reimbursed. It is recommended to use the European Commission&#8217;s template <em>Compensation for trial participants.<\/em><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li><u>Document providing an overview of any agreements<\/u> between the sponsor and the trial sites involved, as well as any compensation arrangements that applies to the trial sites and\/or PIs involved. The agreements are not to be submitted.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<ul>\n<li>All circumstances, such as financial interests and institutional affiliations, which may affect the PIs impartiality must be described for each <em>PI in the Declaration of Interest Form template<\/em> or in another separate document.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Please note that the document Proof of Payment should only be submitted under Part I, this also applies for substantial modification applications.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A brief description of the financing of the study, including information about the financial source(s) and what this funding cover. It is assumed that the intervention period is financially secured. &nbsp; Description of any compensation for the study participants. This also includes a description of how participants&#8217; eventual expenses are to be reimbursed. It is [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":6835,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_cn_metabox_post_checkbox_dont_send_once":false,"_cn_metabox_post_checkbox_dont_send_ever":false,"inline_featured_image":false,"footnotes":""},"categories":[62],"tags":[],"class_list":["post-6841","page","type-page","status-publish","hentry","category-rek-kulmu-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Financing and other arrangements - Rekportalen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Financing and other arrangements - Rekportalen\" \/>\n<meta property=\"og:description\" content=\"A brief description of the financing of the study, including information about the financial source(s) and what this funding cover. It is assumed that the intervention period is financially secured. &nbsp; Description of any compensation for the study participants. This also includes a description of how participants&#8217; eventual expenses are to be reimbursed. It is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/\" \/>\n<meta property=\"og:site_name\" content=\"Rekportalen\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-10T11:34:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rekportalen.no\/wp-content\/uploads\/2025\/07\/rek.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"573\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/general-requirements-and-recommendations-for-a-ctr-application\\\/part-ii-application-national-application\\\/financing-and-other-arrangements\\\/\",\"url\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/general-requirements-and-recommendations-for-a-ctr-application\\\/part-ii-application-national-application\\\/financing-and-other-arrangements\\\/\",\"name\":\"Financing and other arrangements - Rekportalen\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/#website\"},\"datePublished\":\"2025-04-04T09:55:26+00:00\",\"dateModified\":\"2025-07-10T11:34:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/general-requirements-and-recommendations-for-a-ctr-application\\\/part-ii-application-national-application\\\/financing-and-other-arrangements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/general-requirements-and-recommendations-for-a-ctr-application\\\/part-ii-application-national-application\\\/financing-and-other-arrangements\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/general-requirements-and-recommendations-for-a-ctr-application\\\/part-ii-application-national-application\\\/financing-and-other-arrangements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REK KULMU\",\"item\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical Trials Regulation (CTR)\",\"item\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"General requirements and recommendations for a CTR application\",\"item\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/general-requirements-and-recommendations-for-a-ctr-application\\\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Part II application (national application)\",\"item\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/rek-kulmu\\\/clinical-trials-regulation-ctr\\\/general-requirements-and-recommendations-for-a-ctr-application\\\/part-ii-application-national-application\\\/\"},{\"@type\":\"ListItem\",\"position\":6,\"name\":\"Financing and other arrangements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/\",\"name\":\"Rekportalen\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/#organization\",\"name\":\"Rekportalen\",\"url\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/rekportalen.no\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/logo_pms.svg\",\"contentUrl\":\"https:\\\/\\\/rekportalen.no\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/logo_pms.svg\",\"width\":100,\"height\":100,\"caption\":\"Rekportalen\"},\"image\":{\"@id\":\"https:\\\/\\\/rekportalen.no\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Financing and other arrangements - Rekportalen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/","og_locale":"en_US","og_type":"article","og_title":"Financing and other arrangements - Rekportalen","og_description":"A brief description of the financing of the study, including information about the financial source(s) and what this funding cover. It is assumed that the intervention period is financially secured. &nbsp; Description of any compensation for the study participants. This also includes a description of how participants&#8217; eventual expenses are to be reimbursed. It is [&hellip;]","og_url":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/","og_site_name":"Rekportalen","article_modified_time":"2025-07-10T11:34:31+00:00","og_image":[{"width":1200,"height":573,"url":"https:\/\/rekportalen.no\/wp-content\/uploads\/2025\/07\/rek.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/","url":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/","name":"Financing and other arrangements - Rekportalen","isPartOf":{"@id":"https:\/\/rekportalen.no\/en\/#website"},"datePublished":"2025-04-04T09:55:26+00:00","dateModified":"2025-07-10T11:34:31+00:00","breadcrumb":{"@id":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/financing-and-other-arrangements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rekportalen.no\/en\/"},{"@type":"ListItem","position":2,"name":"REK KULMU","item":"https:\/\/rekportalen.no\/en\/rek-kulmu\/"},{"@type":"ListItem","position":3,"name":"Clinical Trials Regulation (CTR)","item":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/"},{"@type":"ListItem","position":4,"name":"General requirements and recommendations for a CTR application","item":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/"},{"@type":"ListItem","position":5,"name":"Part II application (national application)","item":"https:\/\/rekportalen.no\/en\/rek-kulmu\/clinical-trials-regulation-ctr\/general-requirements-and-recommendations-for-a-ctr-application\/part-ii-application-national-application\/"},{"@type":"ListItem","position":6,"name":"Financing and other arrangements"}]},{"@type":"WebSite","@id":"https:\/\/rekportalen.no\/en\/#website","url":"https:\/\/rekportalen.no\/en\/","name":"Rekportalen","description":"","publisher":{"@id":"https:\/\/rekportalen.no\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rekportalen.no\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/rekportalen.no\/en\/#organization","name":"Rekportalen","url":"https:\/\/rekportalen.no\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rekportalen.no\/en\/#\/schema\/logo\/image\/","url":"https:\/\/rekportalen.no\/wp-content\/uploads\/2025\/01\/logo_pms.svg","contentUrl":"https:\/\/rekportalen.no\/wp-content\/uploads\/2025\/01\/logo_pms.svg","width":100,"height":100,"caption":"Rekportalen"},"image":{"@id":"https:\/\/rekportalen.no\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/pages\/6841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/comments?post=6841"}],"version-history":[{"count":2,"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/pages\/6841\/revisions"}],"predecessor-version":[{"id":7534,"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/pages\/6841\/revisions\/7534"}],"up":[{"embeddable":true,"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/pages\/6835"}],"wp:attachment":[{"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/media?parent=6841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/categories?post=6841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rekportalen.no\/en\/wp-json\/wp\/v2\/tags?post=6841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}